Catch recurrence
before imaging does.
Ultra-sensitive ctDNA-based MRD monitoring — designed to detect residual and recurrent disease months before it shows on a scan. From a simple blood draw, repeatable across the survivorship journey.
Why MRD matters.
After curative-intent surgery or first-line therapy, the question every oncologist wants answered is simple: is it coming back? Imaging can miss micrometastatic disease for months. By the time a scan lights up, the window for early intervention has often closed.
ONCO X's MRD platform will make serial molecular surveillance practical in Indian oncology practice — on the same fast, ultra-sensitive chemistry that powers LiquiSmart Lung.
Where we're starting.
- Post-surgical NSCLC — leveraging the LiquiSmart Lung panel
- Colorectal MRD — following the CRC panel launch
- Bladder MRD — surveillance after cystectomy
- Tumor-informed and tumor-naïve workflows in evaluation
- Clinical validation partners engaged
Be the first to know when it launches.
Register your interest — we'll be in touch when MRD monitoring is ready for early-access oncology partners.
Register interest